This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
By forging new relationships and finding novel uses for existing technologies, this year’s top companies are employing creative ways to advance their science.
Sidebar:Active and Recently Completed NIH ELSI Research Projects With passage of time and increasing political relevance, HGP branch's influence is on the rise among decision-makers Beginning this year, the component of the United States human genome initiative that has been sponsoring studies of the ethical, legal, and social implications of the massive genome effort's ground-breaking research will be reporting the first hard resul
Sidebar:Active and Recently Completed NIH ELSI Research Projects With passage of time and increasing political relevance, HGP branch's influence is on the rise among decision-makers Beginning this year, the component of the United States human genome initiative that has been sponsoring studies of the ethical, legal, and social implications of the massive genome effort's ground-breaking research will be reporting the first hard resul
Certain populations have been historically underrepresented in genome sequencing studies, but the NIH, private clinics, and 23andMe and other companies are trying to fix that.
The concept of epigenetic inheritance has long been controversial. Some researchers hope that new data on cross-generational effects of environmental exposures will help settle the debate.
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.